Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema/Dermatitis, Urticaria and Pruritus
Completed
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Drug: Alesion®
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3793
- Registration Number
- NCT02238236
Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 105
- Registration Number
- NCT02238184
Post-Marketing Surveillance Study of Micardis® Plus in Patients With Hypertension
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8135
- Registration Number
- NCT02238275
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
Phase 3
Completed
- Conditions
- Secondary PreventionStroke
- Interventions
- Drug: optional ASA as comedicationDrug: placebo to optional ASA as comedicationDrug: placebo to ASADrug: placebo to dabigatran etexilateDrug: ASA 100 mgDrug: dabigatran etexilate
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5390
- Registration Number
- NCT02239120
- Locations
- 🇩🇪
Klinikum Coburg gGmbH, Coburg, Germany
🇩🇪Klinikzentrum Mitte, Dortmund, Dortmund, Germany
🇩🇪Klinikum Hanau GmbH, Hanau, Germany
Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 595
- Registration Number
- NCT02238158
Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Salmeterol low doseDrug: Serevent® Diskus®Drug: Salmeterol medium doseDrug: Salmeterol high doseDrug: Placebo Diskus®Drug: Placebo HandiHaler®
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 136
- Registration Number
- NCT02238106
Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 374
- Registration Number
- NCT02238132
Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 230
- Registration Number
- NCT02238210
Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole
- First Posted Date
- 2014-09-11
- Last Posted Date
- 2014-09-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 497
- Registration Number
- NCT02236728
The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia
- First Posted Date
- 2014-09-11
- Last Posted Date
- 2014-09-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26814
- Registration Number
- NCT02236741
© Copyright 2025. All Rights Reserved by MedPath